Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 2/20 | 0.43 |
| ▸ | F3 | P13726 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20529773 | 1.00 | FAAH (0.49) | FAAHSMN1; SMN2SLC6A5F7F3 | |
| SCHEMBL20529775 | 1.00 | FAAH (0.49) | FAAHSMN1; SMN2SLC6A5F7F3 | |
| SCHEMBL20529766 | 1.00 | FAAH (0.49) | FAAHSMN1; SMN2SLC6A5F7F3 | |
| SCHEMBL20529780 | 0.95 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5F7F3 | |
| SCHEMBL20529761 | 0.95 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5F7F3 | |
| SCHEMBL20529769 | 0.95 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5F7F3 | |
| SCHEMBL20529767 | 0.95 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5F7F3 | |
| SCHEMBL17079547 | 0.93 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5F7F3 | |
| SCHEMBL17079549 | 0.93 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5F7F3 | |
| SCHEMBL17079556 | 0.93 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110506050-A | Stable modulators of gamma C cytokine activity | BIONIZ LLC | 2019-11-26 | — | — | CN | claimed |
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | Bioniz Therapeutics, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20210324029-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | Bioniz Therapeutics, Inc. | 2021-10-21 | — | — | US | disclosed |
| EP-3606940-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | Bioniz, LLC (US) | 2020-02-12 | — | — | EP | disclosed |
| CN-110506050-A | Stable modulators of gamma C cytokine activity | BIONIZ LLC | 2019-11-26 | — | — | CN | disclosed |
| WO-2018187499-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | BIONIZ, LLC (US) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | IL15, IL2, IL15RA | FAAH 2241/4885SMN1; SMN2 606/4885SLC6A5 3634/4885 |
| US-20210324029-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | IL2, IL2RA, GMFG | FAAH 4632/4885SMN1; SMN2 1305/4885SLC6A5 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.